Abraham Jella-Andrea, Golubnitschaja Olga
Department of Radiology, University of Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany.
Per Med. 2016 Sep;13(5):455-467. doi: 10.2217/pme-2016-0013. Epub 2016 Jul 27.
Hepatocellular carcinoma (HCC) is the fifth most frequent cancer form but the second leading cause of all cancer-related deaths. There are several reasons for high mortality in the HCC cohort: lack of effective screening programs and consequently late diagnosis, multifactorial origin with cumulative risk factors, complex carcinogenesis, tumor heterogeneity, unpredictable impacts of individual microenvironment on tumor development and progression, and, as the consequence, frequently untargeted therapy and cancer resistance toward currently applied treatment approaches. The currently applied 'treat and wait' approach is inappropriate in the overall HCC management. Urgent need in paradigm change toward predictive, preventive and personalized medicine is discussed in this review article. Innovative strategies for an advanced predictive, preventive and personalized medicine approach in the overall HCC management benefiting the patient are presented.
肝细胞癌(HCC)是第五大常见癌症类型,但却是所有癌症相关死亡的第二大主要原因。HCC患者死亡率高有以下几个原因:缺乏有效的筛查项目,从而导致诊断延迟;多因素起源且存在累积风险因素;复杂的致癌过程;肿瘤异质性;个体微环境对肿瘤发展和进展产生不可预测的影响;因此,治疗常常缺乏针对性,且癌症对当前应用的治疗方法产生耐药性。目前采用的“治疗并等待”方法在整体HCC管理中并不合适。本文综述讨论了迫切需要向预测性、预防性和个性化医学转变的范式。文中还介绍了在整体HCC管理中采用先进的预测性、预防性和个性化医学方法以造福患者的创新策略。